Roche drug Tecentriq should also be allowed to be administered subcutaneously
Published: Tuesday, Nov 14th 2023, 07:40
Zurück zu Live Feed
The pharmaceutical company Roche could significantly shorten the treatment of cancer patients in the future. As the company announced on Tuesday, the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of the drug Tecentriq as a subcutaneous injection, i.e. under the skin.
In this form of administration, Tecentriq can be injected in around seven minutes, Roche explained. By comparison, an intravenous injection takes between 30 and 60 minutes. This gives patients, treatment teams and nursing staff more time.
The subcutaneous version of Tecentriq was recommended for all indications for which the drug is already approved as an intravenous therapy. A final decision on approval is expected from the European Commission shortly.
©Keystone/SDA
German 
English 
French 
Spanish 
Arabic